FDA conducts May 27 review of Andrology Laboratory Services, Inc. in Oakbrook Terrace
By R. U. Cooper
The Food and Drug Administration inspected Andrology Laboratory Services, Inc. in Oakbrook Terrace on May 27, targeting human cellular, tissue, and gene therapy operations, according to details on the FDA's website.
The inspection's final summary reported that Andrology Laboratory Services, Inc. did not require any corrective actions for its management practices.
The FDA regularly evaluates facilities nationwide to ensure compliance with agency regulations aimed at protecting public health. Outcomes of these inspections are made available to the public.
Based on its website, the FDA is a government authority tasked with overseeing the safety and quality of human and veterinary drugs, biologics, medical devices and tobacco products.
Information in this article was sourced from the U.S. Food and Drug Administration. The original data is available here.